Aroxybutynin and atomoxetine (AD109) for obstructive sleep apnea: a randomized phase 3 trial (SynAIRgy)
Strollo PJ Jr, et al. Am J Respir Crit Care Med. 2026;212(7):1569-1584.
Select Scientific Publications
Apnimed is committed to advancing research in sleep-related breathing diseases. Below is a selection of key publications and presentations about obstructive sleep apnea (OSA) and our work.
Featured presentations & publications
Aroxybutynin And Atomoxetine (AD109) In Obstructive Sleep Apnea (Breaking News: Clinical Trial Results in Pulmonary Medicine, ATS 2026).
Patel SR, et al. Am J Resp Crit Care Med. 2026;212(suppl 2):aamag286.015.
AD109 Significantly Reduces Snoring in Patients with Obstructive Sleep Apnea.
Gell LK, et al. Am J Respir Crit Care Med. 2026;212(suppl 1):aamag162.6398.
Concomitant Aroxybutynin and Atomoxetine (AD109) with GLP-1 Agonists: An Analysis of the SynAIRgy and LunAIRo Trials in Obstructive Sleep Apnea
Strollo PJ et al. Sleep. 2026;49(Suppl):A264-A262.
Aroxybutynin and Atomoxetine (AD109) in Post-menopausal Women with Obstructive Sleep Apnea.
Mehra R et al. Presented at: CHEST 2026 Annual Meeting.
Latest research updates
Topic
Type
AD109 is an investigational, first-in-class, fixed-dose oral combination of novel anti-muscarinic and a selective norepinephrine reuptake inhibitor for the treatment of OSA. AD109 is designed to target the neuromuscular defect of OSA by improving upper airway muscle activity to help maintain airway patency and prevent airway collapse during sleep.
Nearly 1 billion people with OSA worldwide stop breathing, exposing them to serious, long-term health risks.1
- Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Benjafield AV et al. Lancet Respir Med. 2019;7(8):687-698.
Disclaimer: On this page, you may select links to key publications from peer-reviewed journals as well as to materials presented at scientific conferences relating either to research studies involving Apnimed’s product candidates or the science guiding our discovery, research, and development efforts. The safety and efficacy of any investigational product discussed in these materials has yet to be determined. Note that certain of these materials were authored by unaffiliated third parties and do not represent Apnimed’s views. The content of each work is the property of the respective copyright holder and may not be further distributed without their express permission. The information in these materials may not be current or comprehensive, and Apnimed undertakes no obligation to correct or update such information.
Innovation in OSA: AD109
Advancement of AD109 represents potential new hope for people living with OSA.
Explore Our Product Development Program
Check on the progress of our product development program.